Keyphrases
B7-H3
100%
Ovarian Cancer
66%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Tumor-associated Macrophages
25%
Myeloid-derived Suppressor Cells
16%
Antitumor Activity
16%
Tumor Microenvironment
16%
University of North Carolina
11%
Phase I Clinical Trial
11%
Cancer Tumor
11%
Tumor Model
11%
Immunosuppressive State
8%
Healthy Tissue
8%
CD276
8%
Suitable Target
8%
CD19 Antigen
8%
Leukemia Cancer
8%
Antigen Loss
8%
Solid Tumor Therapy
8%
Melanoma Cancer
8%
Antigenic Drift
8%
Tumor Biopsy
8%
Syngeneic Model
8%
RTK Signaling
8%
Safety Activity
8%
Xenogeneic
8%
Orally Bioavailable
5%
B-cell Malignancies
5%
Ascites
5%
Adoptive Transfer
5%
Prostate Cancer
5%
Macrophages
5%
Molecule Inhibitor
5%
Pancreatic Cancer
5%
Clinical Response
5%
Tumorigenesis
5%
Breast Cancer
5%
Tumor
5%
Medicine and Dentistry
Ovarian Cancer
66%
Chimeric Antigen Receptor
44%
Macrophage
22%
Neoplasm
22%
Myeloid-Derived Suppressor Cell
16%
Tumor Microenvironment
16%
Antineoplastic Activity
16%
Tumor Model
11%
Immunosuppressive Drug
11%
Clinical Study
11%
Tumor Biopsy
8%
Antigenic Drift
8%
CD19 Antigen
8%
Breast Cancer
5%
Pancreas Cancer
5%
Ascites
5%
Leukemia
5%
Carcinogenesis
5%
Cancer
5%
Chimeric Antigen Receptor T-Cell
5%
Solid Malignant Neoplasm
5%
Adoptive Transfer
5%
Nodular Melanoma
5%
Prostate Cancer
5%
B Cell
5%
Immunology and Microbiology
Chimeric Antigen Receptor
100%
Tumor-Associated Macrophage
37%
Antineoplastic Activity
25%
Myeloid-Derived Suppressor Cell
25%
Immunosuppressive Drug
16%
Chimeric Antigen Receptor T-Cell
12%
CD276
12%
Antigenic Drift
12%
CD19 Antigen
12%
Prostate
8%
Syngenic
8%
B Cell
8%
Macrophage
8%